Natural Products from Oxytropis pseudoglandulosa

Natural Products Isolated from Oxytropis pseudoglandulosa

BioCrick provides high-purity natural products and bioactive compounds isolated and purified from natural sources for scientific research.

  • Natural product compounds selected from diverse chemical and biological sources.
  • Broad structural diversity and coverage of biological activities.
  • Product activity information can be supported by published literature, patents and research reports.
  • Natural products can be selected according to source, target, activity and disease research interests.
  • Compounds should be stored according to the product specifications after receipt.

Natural Products from Oxytropis pseudoglandulosa

1 natural product associated with Oxytropis pseudoglandulosa

Natural products and bioactive compounds from Oxytropis pseudoglandulosa
Catalog No. Product Name CAS Number COA
BCN9058 N-Phenethylbenzamide
N-Phenethylbenzamide chemical structure
3278-14-6 COA

References

Extract of Oxytropis pseudoglandulosa inhibits vascular smooth muscle cell proliferation and migration via suppression of ERK1/2 and Akt signaling pathways1.[Pubmed: 29660921]


Excessive vascular smooth muscle cell (VSMC) proliferation and migration accelerate the development of occlusive vascular disease. Therefore, finding a means to control the aberrant proliferation and migration of VSMCs has own clinical significance. In the present study, we examined the feasibility of using extract from medicinal plant Oxytropis pseudoglandulosa (OG) to control pathologic proliferation and migration of VSMCs, which never have been tested. Our data indicate that the extract of OG significantly suppressed proliferation and migration of VSMCs without cytotoxic effect, suggesting the OG extract may be an alternative agent to effectively control the aberrant VSMC proliferation and migration without any serious adverse effect. These data suggest that the extract of OG may be a potent therapeutic agent for the treatment of occlusive vascular disease and warrant further studies to identify the major acting ingredient and to validate in vivo efficacy.